Cresset Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $24.1M | Buy |
417,663
+5,199
| +1% | +$299K | 0.09% | 148 |
|
|
2026
Q1 | $25M | Buy |
412,464
+58,269
| +16% | +$3.4M | 0.11% | 127 |
|
|
2025
Q4 | $19.1M | Buy |
354,195
+22,553
| +7% | +$1.08M | 0.08% | 154 |
|
|
2025
Q3 | $15M | Buy |
331,642
+2,559
| +0.8% | +$120K | 0.07% | 181 |
|
|
2025
Q2 | $15.2M | Sell |
329,083
-106,502
| -24% | -$5.23M | 0.08% | 160 |
|
|
2025
Q1 | $26.6M | Sell |
435,585
-2,943
| -0.7% | -$172K | 0.13% | 104 |
|
|
2024
Q4 | $24.8M | Sell |
438,528
-96,514
| -18% | -$5.39M | 0.12% | 108 |
|
|
2024
Q3 | $27.7M | Buy |
535,042
+97,328
| +22% | +$4.57M | 0.11% | 128 |
|
|
2024
Q2 | $18.2M | Buy |
437,714
+1,301
| +0.3% | +$58.2K | 0.08% | 171 |
|
|
2024
Q1 | $23.7M | Buy |
436,413
+99,360
| +29% | +$5.06M | 0.11% | 116 |
|
|
2023
Q4 | $17.3M | Sell |
337,053
-59,888
| -15% | -$3.14M | 0.1% | 135 |
|
|
2023
Q3 | $23M | Sell |
396,941
-2,019
| -0.5% | -$124K | 0.09% | 112 |
|
|
2023
Q2 | $25.5M | Buy |
398,960
+327,148
| +456% | +$21.9M | 0.03% | 149 |
|
|
2023
Q1 | $4.98M | Sell |
71,812
-298,605
| -81% | -$21.1M | 0.1% | 132 |
|
|
2022
Q4 | $25.8M | Sell |
370,417
-8,952
| -2% | -$675K | 0.33% | 43 |
|
|
2022
Q3 | $27M | Sell |
379,369
-7,482
| -2% | -$543K | 0.34% | 35 |
|
|
2022
Q2 | $30M | Buy |
386,851
+1,195
| +0.3% | +$91K | 0.37% | 32 |
|
|
2022
Q1 | $28.4M | Sell |
385,656
-8,266
| -2% | -$555K | 0.29% | 41 |
|
|
2021
Q4 | $24.6M | Buy |
393,922
+13,464
| +4% | +$790K | 0.24% | 47 |
|
|
2021
Q3 | $22.7M | Buy |
380,458
+3,052
| +0.8% | +$201K | 0.31% | 36 |
|
|
2021
Q2 | $25.2M | Buy |
377,406
+314,093
| +496% | +$20.5M | 0.36% | 30 |
|
|
2021
Q1 | $4.03M | Sell |
63,313
-321,861
| -84% | -$20M | 0.06% | 104 |
|
|
2020
Q4 | $24.1M | Sell |
385,174
-12,583
| -3% | -$774K | 0.39% | 26 |
|
|
2020
Q3 | $24M | Sell |
397,757
-8,463
| -2% | -$509K | 0.45% | 25 |
|
|
2020
Q2 | $23.9M | Buy |
406,220
+5,597
| +1% | +$335K | 0.52% | 25 |
|
|
2020
Q1 | $22.3M | Buy |
400,623
+4,829
| +1% | +$295K | 0.68% | 22 |
|
|
2019
Q4 | $27.2M | Buy |
395,794
+59,404
| +18% | +$3.4M | 0.74% | 19 |
|
|
2019
Q3 | $17.1M | Buy |
336,390
+2,048
| +0.6% | +$96.3K | 0.52% | 26 |
|
|
2019
Q2 | $15.2M | Buy |
334,342
+28,483
| +9% | +$1.33M | 0.47% | 27 |
|
|
2019
Q1 | $14.6M | Buy |
305,859
+17,641
| +6% | +$879K | 0.57% | 19 |
|
|
2018
Q4 | $15M | Buy |
+288,218
| New | +$15.5M | 0.89% | 17 |
|
Other funds holding BMY
Cresset Asset Management's BMY Position: Q2 2026 in Review
Cresset Asset Management increased its Bristol-Myers Squibb (BMY) stake by 1.3% in Q2 2026, buying an estimated $299K and bringing the position to 417,663 shares worth $24.1M. The position accounts for 0.09% of the portfolio, ranked #148.
Cresset Asset Management first reported a position in BMY in Q4 2018 and has held it in 31 quarters since. The position peaked at $30M in Q2 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Cresset Asset Management held 417,663 shares of Bristol-Myers Squibb worth $24.1M as of Q2 2026.
- Cresset Asset Management bought 5,199 Bristol-Myers Squibb shares in Q2 2026, an estimated $299K.
- Bristol-Myers Squibb made up 0.09% of Cresset Asset Management's portfolio in Q2 2026, its #148 holding.
- Cresset Asset Management first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 31 quarters since.
- Cresset Asset Management's Bristol-Myers Squibb position peaked at $30M in Q2 2022.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.